Pancreatic cancer, the fourth leading cause of cancer mortality in the U.S., is resistant to all standard therapies (overall 5-year survival rate, 5%), highlighting the need for novel treatments. T cells have the capacity to actively infiltrate fibrotic tissue, and adoptively transferred, in v/Y/'o-expanded cytotoxic T lymphocytes (CTLs) targeting tumor-associated antigens can effectively traffic to distant tumor sites, infiltrate even bulky tumor masses and eradicate disseminated tumor cells in a range of malignancies, including Hodgkin lymphoma, nasopharyngeal carcinoma, neuroblastoma and melanoma. Whether this therapy can be successfully extended to the treatment of patients with pancreatic cancer will likely depend on the development of strategies to ensure tumor specificity and circumvention of the adverse effects of the tumor microenvironment, which limits the in vivo persistence and function of the transferred T cells. In this new Project 2 { A. Leen and W. Fisher) will generate cytotoxic T lymphocyte (CTL) lines that target mesothelin (MSLN), a glycoprotein overexpressed in 80-90% of pancreatic carcinomas and containing epitopes recognized by T cells. These cells will then be engineered to express a novel chimeric cytokine receptor (IL4/7R) that should allow them to resist the tumor microenvironment by inverting the function of the immunoinhibitory cytokine IL4 to transmit an immunostimulatory signal that will sustain the expansion and cytolytic function of the infused cells (Aim 1). This strategy, to be tested in a phase I clinical trial in patients with advanced pancreatic cancer (Aims 2 and 3) should safely ensure the sustained function of tumor-targeted T cells in vivo, even in the immunosuppressive tumor microenvironment, and enhance the potency of adoptively transferred T cells. Engineering mesothelin-specific T cells to express a chimeric cytokine receptor that binds the abundant Th2 cytokine IL4, while maintaining a Thi effector phenotype and cytotoxic function, represents a novel achievement in the field, one that may well advance treatment for this devastating tumor. Our project could potentially make use of the icaspQ safety gene developed by Project 1 and the CAR targeting CAF that Project 4 is developing and can provide additional means of enhancing anti-tumor activity to all projects in the program.

Public Health Relevance

Few other solid tumors carry the dire prognosis of pancreatic cancer. To meet the urgent need for useful treatment of this malignancy, investigators in this project have engineered a chimeric cytokine receptor that will both stimulate the expansion and persistence of the modified tumor-directed T cells, as well as protect them from the adverse effects of the surrounding microenvironment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094237-12
Application #
8933444
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (O1))
Program Officer
Merritt, William D
Project Start
2014-02-01
Project End
2018-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
12
Fiscal Year
2014
Total Cost
$247,486
Indirect Cost
$89,098
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
DeRenzo, Christopher; Gottschalk, Stephen (2014) Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol 804:323-40
Rouce, Rayne H; Louis, Chrystal U; Heslop, Helen E (2014) Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 21:476-81
Perna, Serena K; Pagliara, Daria; Mahendravada, Aruna et al. (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20:131-9
Leen, Ann M; Heslop, Helen E; Brenner, Malcolm K (2014) Antiviral T-cell therapy. Immunol Rev 258:12-29
Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen et al. (2014) Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123:3895-905
Chia, Whay-Kuang; Teo, Marissa; Wang, Who-Whong et al. (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22:132-9
Anurathapan, Usanarat; Leen, Ann M; Brenner, Malcolm K et al. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:713-33
Anurathapan, Usanarat; Chan, Robert C; Hindi, Hakeem F et al. (2014) Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22:623-33
Heslop, Helen E (2014) Combining drugs and biologics to treat nasopharyngeal cancer. Mol Ther 22:8-9
Lee, Daniel W; Gardner, Rebecca; Porter, David L et al. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188-95

Showing the most recent 10 out of 114 publications